Glenview Capital Management’s AbbVie ABBV Stock Holding History

Glenview Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.5M	Buy	+148,913	New	+$32M	0.68%	32
2018 Q1	–	Sell	-1,364,449	Closed	-$132M	–	56
2017 Q4	$132M	Sell	1,364,449 -3,976,883	-74%	-$375M	0.71%	39
2017 Q3	$475M	Sell	5,341,332 -768,838	-13%	-$58.5M	2.75%	13
2017 Q2	$443M	Sell	6,110,170 -1,191,797	-16%	-$80.1M	2.87%	13
2017 Q1	$476M	Sell	7,301,967 -1,815,002	-20%	-$114M	3.16%	12
2016 Q4	$571M	Buy	9,116,969 +3,086,828	+51%	+$188M	3.86%	7
2016 Q3	$380M	Sell	6,030,141 -6,424,347	-52%	-$416M	2.72%	13
2016 Q2	$771M	Sell	12,454,488 -1,232,100	-9%	-$75.1M	5.45%	5
2016 Q1	$782M	Buy	13,686,588 +141,773	+1%	+$7.9M	5.72%	5
2015 Q4	$802M	Sell	13,544,815 -2,626,088	-16%	-$151M	4.52%	6
2015 Q3	$880M	Sell	16,170,903 -1,685,038	-9%	-$110M	4.37%	4
2015 Q2	$1.2B	Buy	17,855,941 +15,412,309	+631%	+$1.01B	4.75%	3
2015 Q1	$143M	Buy	+2,443,632	New	+$148M	0.65%	50

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Glenview Capital Management's ABBV Position: Q2 2026 in Review

Glenview Capital Management opened a new position in AbbVie (ABBV) in Q2 2026: 148,913 shares worth $37.5M. The stake represents 0.68% of the portfolio and ranks #32 among its holdings. This is a return to the name: Glenview Capital Management previously reported a position in ABBV as recently as Q4 2017.

Glenview Capital Management first reported a position in ABBV in Q1 2015 and has held it in 13 quarters since. The position peaked at $1.2B in Q2 2015. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Glenview Capital Management held 148,913 shares of AbbVie worth $37.5M as of Q2 2026.
AbbVie was a new Glenview Capital Management position in Q2 2026.
AbbVie made up 0.68% of Glenview Capital Management's portfolio in Q2 2026, its #32 holding.
Glenview Capital Management first reported a position in AbbVie in Q1 2015 and has held it in 13 quarters since.
Glenview Capital Management's AbbVie position peaked at $1.2B in Q2 2015.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Glenview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.